DAFNA Capital Management LLC reduced its holdings in shares of BrainsWay Ltd. (NASDAQ:BWAY - Free Report) by 23.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 193,208 shares of the company's stock after selling 58,138 shares during the quarter. DAFNA Capital Management LLC owned approximately 1.03% of BrainsWay worth $1,822,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently modified their holdings of BWAY. Phoenix Financial Ltd. lifted its stake in BrainsWay by 100.8% in the 4th quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company's stock valued at $4,552,000 after buying an additional 242,366 shares in the last quarter. ARK Investment Management LLC purchased a new stake in shares of BrainsWay in the fourth quarter valued at $1,656,000. MYDA Advisors LLC boosted its stake in shares of BrainsWay by 100.2% during the fourth quarter. MYDA Advisors LLC now owns 120,100 shares of the company's stock valued at $1,133,000 after acquiring an additional 60,100 shares during the last quarter. Zuckerman Investment Group LLC increased its position in BrainsWay by 346.4% during the 4th quarter. Zuckerman Investment Group LLC now owns 67,000 shares of the company's stock worth $667,000 after purchasing an additional 51,991 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in BrainsWay in the 4th quarter valued at about $149,000. Hedge funds and other institutional investors own 30.11% of the company's stock.
BrainsWay Trading Down 1.8 %
Shares of BrainsWay stock traded down $0.16 during trading hours on Friday, reaching $8.71. 12,443 shares of the company's stock were exchanged, compared to its average volume of 70,611. The firm has a market capitalization of $164.38 million, a price-to-earnings ratio of 87.11 and a beta of 1.25. BrainsWay Ltd. has a 52-week low of $5.13 and a 52-week high of $11.79. The company has a fifty day moving average of $9.10 and a 200-day moving average of $9.71.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of BrainsWay in a research note on Wednesday, March 12th.
Get Our Latest Analysis on BWAY
BrainsWay Company Profile
(
Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Read More
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
